Fletcher Spaght

PhaseBio Pharmaceuticals, Inc., established in 2002 and based in Malvern, Pennsylvania, is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for cardiopulmonary diseases. Its primary focus is on PB2452, a reversal agent for the antiplatelet drug ticagrelor, currently in Phase III trials for managing uncontrolled bleeding events or urgent surgeries. Additionally, PhaseBio is developing PB1046, a fusion protein in Phase IIb trials for treating pulmonary arterial hypertension, and PB6440, an oral agent for resistant hypertension. The company's proprietary technology, elastin-like polypeptides (ELPs), enhances the stability, bioavailability, and efficacy of proteins and peptides, aiming to improve patient outcomes and reduce side effects.

Cheetah Medical, Inc. is a medical technology company specializing in the development and commercialization of non-invasive solutions for monitoring cardiac output and hemodynamics. Its flagship product, the CHEETAH NICOM system, is a non-invasive cardiac output monitor that aids in clinical applications such as fluid optimization, hemodynamic diagnosis, and drug titration. The system provides valuable insights into conditions like hypovolemic shock, septic shock, and acute renal failure, among others. CE marked and FDA cleared, the CHEETAH NICOM is recognized for its equivalence to invasive monitoring systems. Cheetah Medical distributes its products to medical centers across numerous countries, including the United States, Australia, and several European and Asian nations. Founded in 2000 and headquartered in Newton Center, Massachusetts, Cheetah Medical also maintains offices in Vancouver, Washington, Tel Aviv, Israel, and the United Kingdom, and operates as a subsidiary of Baxter International Inc. The company remains dedicated to research and development, collaborating closely with clinicians to enhance patient outcomes.

HistoSonics, Inc. is a medical technology company based in Plymouth, Minnesota, specializing in non-invasive tumor ablation systems. The company has developed the Edison Platform, which employs advanced imaging and proprietary sensing technology to deliver precise sonic beam therapy. This innovative platform utilizes histotripsy and focused sound energy to liquefy and destroy targeted tissues at the sub-cellular level, enabling personalized treatments. HistoSonics' technology allows physicians to monitor the treatment in real time, offering a safe alternative to traditional interventional and surgical methods, minimizing undesirable side effects often associated with these approaches. Incorporated in 2009, HistoSonics aims to enhance treatment outcomes through its pioneering non-invasive solutions.

Swift Biosciences Inc. is a biotechnology company based in Ann Arbor, Michigan, specializing in the development and commercialization of next-generation sequencing (NGS) library preparation kits for genomics and clinical research. The company offers a comprehensive range of products, including RNA library kits, amplicon panels, hybridization capture kits, and specialized kits for cancer gene profiling and COVID-19 testing. Swift Biosciences aims to streamline NGS sample preparation processes through innovative reagents and protocols, enhancing the usability of data obtained from sequencing instruments. Its offerings cater to various applications such as whole-genome sequencing, metagenomics, and the analysis of circulating tumor cells. The company operates through a network of distributors across the Asia Pacific, Europe, the Middle East, and South America, and was incorporated in 2009.

PhaseBio Pharmaceuticals, Inc., established in 2002 and based in Malvern, Pennsylvania, is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for cardiopulmonary diseases. Its primary focus is on PB2452, a reversal agent for the antiplatelet drug ticagrelor, currently in Phase III trials for managing uncontrolled bleeding events or urgent surgeries. Additionally, PhaseBio is developing PB1046, a fusion protein in Phase IIb trials for treating pulmonary arterial hypertension, and PB6440, an oral agent for resistant hypertension. The company's proprietary technology, elastin-like polypeptides (ELPs), enhances the stability, bioavailability, and efficacy of proteins and peptides, aiming to improve patient outcomes and reduce side effects.

CardioFocus, Inc. is a biotechnology company based in Marlborough, Massachusetts, that specializes in the development of innovative medical devices for the treatment of cardiac disorders, particularly atrial fibrillation. The company offers a range of products, including the HeartLight Endoscopic Ablation System, which utilizes visually guided laser balloon technology to achieve precise pulmonary vein isolation. This system is complemented by the HeartLight Excalibur Balloon, designed for stable contact and effective lesion creation through direct tissue visualization, and the HeartLight X3 System, which allows for controlled lesion formation. CardioFocus focuses on providing electrophysiologists with advanced tools that enhance the precision and control of ablation treatments, utilizing disposable fiber optic catheters for improved visualization of cardiac anatomy and the treatment of arrhythmias. Founded in 1990, CardioFocus continues to pursue advancements in ablation technologies to better meet the needs of patients and healthcare providers.

Cheetah Medical, Inc. is a medical technology company specializing in the development and commercialization of non-invasive solutions for monitoring cardiac output and hemodynamics. Its flagship product, the CHEETAH NICOM system, is a non-invasive cardiac output monitor that aids in clinical applications such as fluid optimization, hemodynamic diagnosis, and drug titration. The system provides valuable insights into conditions like hypovolemic shock, septic shock, and acute renal failure, among others. CE marked and FDA cleared, the CHEETAH NICOM is recognized for its equivalence to invasive monitoring systems. Cheetah Medical distributes its products to medical centers across numerous countries, including the United States, Australia, and several European and Asian nations. Founded in 2000 and headquartered in Newton Center, Massachusetts, Cheetah Medical also maintains offices in Vancouver, Washington, Tel Aviv, Israel, and the United Kingdom, and operates as a subsidiary of Baxter International Inc. The company remains dedicated to research and development, collaborating closely with clinicians to enhance patient outcomes.

Metabolon, Inc. is a health technology company specializing in metabolomics, focusing on the development of diagnostic tests and analytical methods for early disease detection and precision medicine. The company offers a range of clinical diagnostics, including QUANTOSE IR for measuring insulin resistance, QUANTOSE IGT for assessing glucose tolerance, and Meta IMD for identifying metabolites linked to inherited metabolic disorders. In addition to its diagnostic capabilities, Metabolon provides customizable research services and multiomics solutions to support academic and commercial investigations across various life science sectors. Its technologies are applicable in areas such as cardiovascular health, diabetes, oncology, and respiratory disorders. Founded in 2000 and headquartered in Morrisville, North Carolina, with additional offices in Europe and sales locations in the UK, Spain, and China, Metabolon collaborates with numerous strategic partners in the pharmaceutical and biotechnology industries to enhance research and development outcomes.

Swift Biosciences Inc. is a biotechnology company based in Ann Arbor, Michigan, specializing in the development and commercialization of next-generation sequencing (NGS) library preparation kits for genomics and clinical research. The company offers a comprehensive range of products, including RNA library kits, amplicon panels, hybridization capture kits, and specialized kits for cancer gene profiling and COVID-19 testing. Swift Biosciences aims to streamline NGS sample preparation processes through innovative reagents and protocols, enhancing the usability of data obtained from sequencing instruments. Its offerings cater to various applications such as whole-genome sequencing, metagenomics, and the analysis of circulating tumor cells. The company operates through a network of distributors across the Asia Pacific, Europe, the Middle East, and South America, and was incorporated in 2009.

SurgiQuest is a technology company based in Orange, Connecticut, specializing in solutions for minimally invasive surgery. Established in 2006, the company is known for its AirSeal technology, which creates an air curtain to maintain an insufflated and airtight environment during laparoscopic and laparoscopic-assisted procedures. SurgiQuest's focus spans various surgical fields, including bariatric, colorectal, general, gynecological, and urologic surgery.

Juventas Therapeutics, Inc. is a clinical-stage biotechnology company based in Cleveland, Ohio, that focuses on developing non-viral gene therapies aimed at repairing the body’s natural processes. Established in 2007, the company specializes in treating non-healing wounds associated with advanced peripheral artery disease. Its lead therapy, JVS-100, utilizes stromal cell-derived factor-1 (SDF-1), a naturally occurring signaling protein that helps recruit the body’s stem cells to promote tissue repair. Juventas has successfully transitioned its therapeutic platform from concept to mid-stage clinical trials, supported by various investors and non-dilutive grants from organizations such as the Ohio Third Frontier and the Cleveland Clinic. The company aims to address life-threatening diseases, particularly cardiovascular conditions and ischemic disorders, through its innovative regenerative therapies.

PhaseBio Pharmaceuticals, Inc., established in 2002 and based in Malvern, Pennsylvania, is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for cardiopulmonary diseases. Its primary focus is on PB2452, a reversal agent for the antiplatelet drug ticagrelor, currently in Phase III trials for managing uncontrolled bleeding events or urgent surgeries. Additionally, PhaseBio is developing PB1046, a fusion protein in Phase IIb trials for treating pulmonary arterial hypertension, and PB6440, an oral agent for resistant hypertension. The company's proprietary technology, elastin-like polypeptides (ELPs), enhances the stability, bioavailability, and efficacy of proteins and peptides, aiming to improve patient outcomes and reduce side effects.

Cayenne Medical, Inc. is a medical device company specializing in soft tissue reconstruction solutions for the knee, shoulder, and extremities. Founded in 2005 and based in Scottsdale, Arizona, the company designs and markets a range of products aimed at improving surgical outcomes in sports medicine. Its offerings include the AperFix System, which facilitates anterior cruciate ligament (ACL) reconstruction using soft tissue grafts, as well as the AperFix II Cannulated Tibial Device and the AperFix Femoral Implant for anatomical soft tissue fixation. Cayenne Medical also provides the CrossFix II System for meniscal repair, the iFix for bone-tendon fixation, and the Cayenne Mirror Partial Knee System for early-stage knee arthritis treatment. In the shoulder category, the Quattro System addresses rotator cuff and labral repairs. Cayenne Medical operates as a subsidiary of Zimmer Biomet Holdings, enhancing its capacity to deliver innovative medical solutions.

Metabolon, Inc. is a health technology company specializing in metabolomics, focusing on the development of diagnostic tests and analytical methods for early disease detection and precision medicine. The company offers a range of clinical diagnostics, including QUANTOSE IR for measuring insulin resistance, QUANTOSE IGT for assessing glucose tolerance, and Meta IMD for identifying metabolites linked to inherited metabolic disorders. In addition to its diagnostic capabilities, Metabolon provides customizable research services and multiomics solutions to support academic and commercial investigations across various life science sectors. Its technologies are applicable in areas such as cardiovascular health, diabetes, oncology, and respiratory disorders. Founded in 2000 and headquartered in Morrisville, North Carolina, with additional offices in Europe and sales locations in the UK, Spain, and China, Metabolon collaborates with numerous strategic partners in the pharmaceutical and biotechnology industries to enhance research and development outcomes.

SironRX is developing novel therapies exclusively licensed from Juventas Therapeutics and Cleveland Clinic that promote dermal wound repair and reduce scarring. Our lead product is a clinically tested biopharmaceutical that encodes Stromal cell-Derived Factor-1 (SDF-1). SDF-1 is key molecule responsible for activating natural repair processes after tissue injury through prevention of cell death and recruitment of stem cells to the damaged organ. Studies from several laboratories suggest the therapeutic potential of SDF-1 for treatment of a range of wounds such as post-surgical incisions, chronic diabetic ulcers and burns. Development of a cost-effective interactive wound therapy that can be topically administered at the site-of-injury or in chronic wound care settings with the potential to significantly improve function of the damaged tissue will have a major impact on the multi-billion dollar advanced wound management market.

SurgiQuest is a technology company based in Orange, Connecticut, specializing in solutions for minimally invasive surgery. Established in 2006, the company is known for its AirSeal technology, which creates an air curtain to maintain an insufflated and airtight environment during laparoscopic and laparoscopic-assisted procedures. SurgiQuest's focus spans various surgical fields, including bariatric, colorectal, general, gynecological, and urologic surgery.

CardioFocus, Inc. is a biotechnology company based in Marlborough, Massachusetts, that specializes in the development of innovative medical devices for the treatment of cardiac disorders, particularly atrial fibrillation. The company offers a range of products, including the HeartLight Endoscopic Ablation System, which utilizes visually guided laser balloon technology to achieve precise pulmonary vein isolation. This system is complemented by the HeartLight Excalibur Balloon, designed for stable contact and effective lesion creation through direct tissue visualization, and the HeartLight X3 System, which allows for controlled lesion formation. CardioFocus focuses on providing electrophysiologists with advanced tools that enhance the precision and control of ablation treatments, utilizing disposable fiber optic catheters for improved visualization of cardiac anatomy and the treatment of arrhythmias. Founded in 1990, CardioFocus continues to pursue advancements in ablation technologies to better meet the needs of patients and healthcare providers.

HTG Molecular Diagnostics is a commercial-stage life sciences company based in Tucson, Arizona, that specializes in precision medicine through its innovative molecular profiling technology. The company provides a range of products, including instruments, assay kits, and software, which are integrated into the HTG EdgeSeq platform. This platform automates sample processing and allows for the rapid, reliable profiling of numerous molecular targets from minimal biological samples. HTG's offerings include various molecular profiling panels designed for oncology and immuno-oncology applications, among others. The company serves a diverse clientele, including biopharmaceutical companies, academic research institutions, and molecular testing laboratories, distributing its products directly in the United States and Europe, as well as through international distributors. HTG Molecular Diagnostics has established partnerships with industry leaders to enhance its research and development efforts, further solidifying its role in advancing diagnostic applications and translational medicine. The company was founded in 1997 and was previously known as HTG, Inc. before rebranding in 2011.

HistoSonics, Inc. is a medical technology company based in Plymouth, Minnesota, specializing in non-invasive tumor ablation systems. The company has developed the Edison Platform, which employs advanced imaging and proprietary sensing technology to deliver precise sonic beam therapy. This innovative platform utilizes histotripsy and focused sound energy to liquefy and destroy targeted tissues at the sub-cellular level, enabling personalized treatments. HistoSonics' technology allows physicians to monitor the treatment in real time, offering a safe alternative to traditional interventional and surgical methods, minimizing undesirable side effects often associated with these approaches. Incorporated in 2009, HistoSonics aims to enhance treatment outcomes through its pioneering non-invasive solutions.

PhaseBio Pharmaceuticals, Inc., established in 2002 and based in Malvern, Pennsylvania, is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for cardiopulmonary diseases. Its primary focus is on PB2452, a reversal agent for the antiplatelet drug ticagrelor, currently in Phase III trials for managing uncontrolled bleeding events or urgent surgeries. Additionally, PhaseBio is developing PB1046, a fusion protein in Phase IIb trials for treating pulmonary arterial hypertension, and PB6440, an oral agent for resistant hypertension. The company's proprietary technology, elastin-like polypeptides (ELPs), enhances the stability, bioavailability, and efficacy of proteins and peptides, aiming to improve patient outcomes and reduce side effects.

Metabolon, Inc. is a health technology company specializing in metabolomics, focusing on the development of diagnostic tests and analytical methods for early disease detection and precision medicine. The company offers a range of clinical diagnostics, including QUANTOSE IR for measuring insulin resistance, QUANTOSE IGT for assessing glucose tolerance, and Meta IMD for identifying metabolites linked to inherited metabolic disorders. In addition to its diagnostic capabilities, Metabolon provides customizable research services and multiomics solutions to support academic and commercial investigations across various life science sectors. Its technologies are applicable in areas such as cardiovascular health, diabetes, oncology, and respiratory disorders. Founded in 2000 and headquartered in Morrisville, North Carolina, with additional offices in Europe and sales locations in the UK, Spain, and China, Metabolon collaborates with numerous strategic partners in the pharmaceutical and biotechnology industries to enhance research and development outcomes.

PhaseBio Pharmaceuticals, Inc., established in 2002 and based in Malvern, Pennsylvania, is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for cardiopulmonary diseases. Its primary focus is on PB2452, a reversal agent for the antiplatelet drug ticagrelor, currently in Phase III trials for managing uncontrolled bleeding events or urgent surgeries. Additionally, PhaseBio is developing PB1046, a fusion protein in Phase IIb trials for treating pulmonary arterial hypertension, and PB6440, an oral agent for resistant hypertension. The company's proprietary technology, elastin-like polypeptides (ELPs), enhances the stability, bioavailability, and efficacy of proteins and peptides, aiming to improve patient outcomes and reduce side effects.

Interactive Supercomputing, Inc. was founded in 2004 and is headquartered in Waltham, Massachusetts. The company developed Star-P, an interactive parallel computing platform designed for automatic parallelization and execution of desktop simulation applications across various sectors, including biomedical, financial, and government laboratory research. Star-P enables users to perform scientific, engineering, or analytical computations on array or matrix-based data by leveraging parallel architectures such as multi-core workstations, multi-processor systems, and distributed memory clusters, as well as cloud-based environments. In addition to its software platform, Interactive Supercomputing provides customer support, professional services, application consulting, and training services. The company markets its products through authorized resellers both in the United States and internationally. In September 2009, Interactive Supercomputing was acquired by Microsoft Corporation.

Quick Study Radiology provides digital imaging solutions for community hospitals, radiology and oncology practices, and imaging centers. The company offers image and data archiving, and disaster recovery services; monitoring and security services; and networking and web distribution services. It also provides picture archiving and communication systems for community hospitals and other facilities, and radiology information systems to store, manage, and distribute patient’s data and imagery. Quick Study Radiology was founded in 1999 and is based in Saint Louis, Missouri.

BioTrove, Inc. specializes in developing and manufacturing advanced technology platforms for life science and drug discovery research. The company offers the OpenArray platform, which facilitates relative gene expression analysis and supports research across various fields such as agriculture, disease research, and public health. Additionally, BioTrove provides the RapidFire technology platform, designed for screening difficult drug targets through mass spectrometry-based assay development. This includes the RapidFire mass spectrometry hardware system, which serves as a native detection technology for drug screening and in vitro ADME applications. With a focus on high-throughput genomic analysis, BioTrove's systems enable rapid, simultaneous polymerase chain reactions (PCR) on multiple samples, thereby enhancing the efficiency of research and development processes in diverse scientific areas.

Courtagen Life Sciences, Inc. is a biotechnology company based in Woburn, Massachusetts, specializing in genetic testing services. The company provides a range of clinical genetic tests focused on neurological conditions, including developmental delay, intellectual disability, autism spectrum disorders, epilepsy, and mitochondrial disorders. Its offerings include comprehensive analyses such as epiSEEK Comprehensive and epiSEEK Focus, which assess genes associated with neurological function and seizure disorders, respectively. Additionally, Courtagen offers tests for drug metabolism related to epilepsy, as well as panels for neurodevelopmental and lysosomal storage disorders. The company also provides next generation sequencing services to support research in target discovery, clinical development, and companion diagnostics. Founded in 2003, Courtagen Life Sciences aims to empower physicians, families, and children affected by neurological disorders through advanced genetic insights.

GlycoFi is a biotech firm based in Lebanon, New Hampshire, focused on developing biotherapeutics through its innovative glycan optimization technology. The company has engineered a library of yeast strains that enable precise human glycosylation, resulting in therapeutic proteins suitable for drug development. GlycoFi aims to establish its own pipeline of therapeutic products while also collaborating with other pharmaceutical companies to enhance their drug offerings. Founded in 2000, GlycoFi operates as a subsidiary of Merck & Co., Inc., further expanding its capabilities in the biotherapeutics landscape.

Quick Study Radiology provides digital imaging solutions for community hospitals, radiology and oncology practices, and imaging centers. The company offers image and data archiving, and disaster recovery services; monitoring and security services; and networking and web distribution services. It also provides picture archiving and communication systems for community hospitals and other facilities, and radiology information systems to store, manage, and distribute patient’s data and imagery. Quick Study Radiology was founded in 1999 and is based in Saint Louis, Missouri.

Ventaira Pharmaceuticals is an emerging specialty pharmaceutical company dedicated to the development of innovative inhalation products. The company employs its proprietary electrohydrodynamic aerosolization and formulation technologies to create new inhaled drugs. Among its key products are fentanyl, aimed at treating breakthrough pain, and salmeterol, used for asthma management. Ventaira Pharmaceuticals focuses on advancing its unique technologies to enhance drug delivery and improve treatment options for patients.

Quick Study Radiology provides digital imaging solutions for community hospitals, radiology and oncology practices, and imaging centers. The company offers image and data archiving, and disaster recovery services; monitoring and security services; and networking and web distribution services. It also provides picture archiving and communication systems for community hospitals and other facilities, and radiology information systems to store, manage, and distribute patient’s data and imagery. Quick Study Radiology was founded in 1999 and is based in Saint Louis, Missouri.

Proteus Digital Health, Inc. was a digital medicines company headquartered in Redwood City, California, founded in 2001. It specialized in developing innovative products and services that integrated pharmaceuticals with ingestible sensors, wearable technology, mobile applications, and cloud computing. The company's offerings included ingestible sensors that communicated medication adherence, wearable sensor patches to monitor physiological responses, and digital platforms for data analytics. These technologies aimed to empower patients and their families in managing health, while providing healthcare providers with tools to enhance decision-making and optimize treatment outcomes. In November 2020, Proteus Digital Health filed for Chapter 11 bankruptcy and subsequently ceased operations.

Ventaira Pharmaceuticals is an emerging specialty pharmaceutical company dedicated to the development of innovative inhalation products. The company employs its proprietary electrohydrodynamic aerosolization and formulation technologies to create new inhaled drugs. Among its key products are fentanyl, aimed at treating breakthrough pain, and salmeterol, used for asthma management. Ventaira Pharmaceuticals focuses on advancing its unique technologies to enhance drug delivery and improve treatment options for patients.